global glp-1 obesity drug market size forecast 2030 Receptor Agonist Size, The Global Obesity Therapeutics Market:

doi: 10.1186/s12902-021-00908-1

Collectively, GLP-1-RAs are involved in the regulation of DNP mainly through the suppression of matrix remodeling, inflammation, oxidative stress, and mitochondrial dysfunction, as well as the improvement of neural structure and function [90,91,92,93] (Fig

On a more positive note, new research also recently found a link between chronic obstructive pulmonary disease (COPD) symptoms and GLP-1 medications

Beyond thyroidal hyperfunction, Graves disease may manifest with extra-thyroidal complications, most notably thyroid-associated orbitopathy, in which fibroblasts and preadipocytes in the orbit express the TSHR and insulin-like growth factor 1 receptor (IGF-1R), leading to tissue expansion, edema, and fibrosis under autoantibody stimulation [19,20]

doi: 10.1186/s12933-022-01604-7 [DOI] [PMC free article] [PubMed] [Google Scholar] 26.Abbasi J

[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Rezaei S., Tabrizi R., Nowrouzi-Sohrabi P., et al